22 April 2022  
EMA/CHMP/223560/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Elonva 
corifollitropin alfa 
On 22 April 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Elonva. The marketing authorisation holder for this medicinal product is Organon N.V. 
The CHMP adopted a new indication for the treatment of hypogonadotropic hypogonadism. 
For information, the full indications for Elonva will be as follows:2 
Elonva is indicated for Controlled Ovarian Stimulation (COS) in combination with a Gonadotropin 
Releasing Hormone (GnRH) antagonist for the development of multiple follicles in women 
participating in an Assisted Reproductive Technology (ART) program. 
Elonva is indicated for the treatment of adolescent males (14 years and older) with 
hypogonadotropic hypogonadism, in combination with human Chorionic Gonadotropin 
(hCG). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
 
 
